TY 9591
Alternative Names: TY-9591Latest Information Update: 26 Jun 2025
At a glance
- Originator TYK Medicine
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- No development reported Brain metastases; Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical study in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 27 Dec 2024 TYK Medicines completes a pharmacokinetics phase I pharmacokinetics trial in healthy chinese subjects in China (PO) (NCT06255951)
- 13 Nov 2024 TYK Medicines completes phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease) in China (PO) (NCT05146219)